Safety and efficacy of pembrolizumab prior to allogeneic stem cell transplant in Acute Myeloid Leukemia

Up-regulation of inhibitory receptors, such as programmed death-1 (PD-1), is an integral component of tumor immune escape, chemotherapy resistance, and disease progression, features which have been identified in acute myeloid leukemia (AML).1 –4 Since the approval of pembrolizumab for metastatic melanoma in September 2014, we have seen an immunologic renaissance unfold with transformative changes in in the management of a growing list of cancers. As of April 2021, seven anti-PD-1/PD-L1 monoclonal antibodies have been approved across 19 different hematologic and solid malignancies, as well as two tissue-agnostic conditions (e.g.

Source: Biology of Blood and Marrow Transplantation - August 30, 2021 Category: Hematology Authors: Nicholas P. Tschernia, Vaibhav Kumar, Dominic T. Moore, Benjamin G. Vincent, Catherine C. Coombs, Hendrik Van Deventer, Matthew C. Foster, Amy E. DeZern, Leo Luznik, Marcie L. Riches, Jonathan S. Serody, Ivana Gojo, Joshua F. Zeidner Source Type: research